BioSpace News Archive

Nuvo Group announced today that it has completed the first phase of its collaboration agreement with Israel’s Sheba Medical Center’s “Sheba BEYOND”, one of the Top Ten medical centers in the world (NEWSWEEK) and a global leader in biotechnological innovation.

Harmony Biosciences Holdings, Inc. today announced that Harmony’s management will participate in the following upcoming investor conference.

Nuvaxovid™ is New Zealand’s first and only protein-based COVID-19 vaccine Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine.

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to five drug targets.

Mytide Therapeutics has partnered with Agilent, a global leader in life science, diagnostic and applied chemical markets.

Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).

Sonoma Biotherapeutics, Inc. today announced the appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH, to its Board of Directors.

Moderna, Inc. today announced that James Mock has been appointed as Moderna’s Chief Financial Officer, beginning September 6, 2022.

Kriya Therapeutics, Inc announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.